Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications by Leto, G. et al.
Clinical & Experimental Metastasis 21: 91–106, 2004.
© 2004 Kluwer Academic Publishers. Printed in the Netherlands. 91
Review
Cathepsin D expression levels in nongynecological solid tumors: Clinical and
therapeutic implications
Gaetano Leto, Francesca M. Tumminello, Marilena Crescimanno, Carla Flandina & Nicola Gebbia
Section of Chemotherapy, Department of Oncology, Policlinico Universitario ‘P. Giaccone’, Palermo, Italy
Received 19 September 2003; accepted in revised form 13 January 2004
Key words: cathepsin D, lysosomal proteinases, matrix-metalloproteinases, metastasis, neoplasm, plasminogen activator,
prognosis, tumor progression
Abstract
Cathepsin D is a lysosomal acid proteinase which is involved in the malignant progression of breast cancer and other
gynecological tumors. Clinical investigations have shown that in breast cancer patients cathepsin D overexpression was
significantly correlated with a shorter free-time disease and overall survival, whereas in patients with ovarian or endometrial
cancer this phenomenon was associated with tumor aggressiveness and a degree of chemoresistance to various antitumor
drugs such as anthracyclines, cis-platinum and vinca alkaloids. Therefore, a lot of research has been undertaken to evaluate
the role and the prognostic value of cathepsin D also in other solid neoplasms. However, conflicting results have been
generated from these studies. The discrepancies in these results may, in part, be explained with the different methodological
approaches used in order to determine the levels of expression of the enzyme in tumor tissues and body fluids. Further
investigations using well-standardized techniques may better define the clinical significance of cathepsin D expression in
solid tumors. Nevertheless, evidence emerging from these studies indicates that this proteinase seems to facilitate early
phases of tumor progression such as cell proliferation and local dissemination. These findings support the concept that
cathepsin D may be a useful marker for identifying patients with highly malignant tumor phenotypes who may need more
aggressive clinical treatment; this enzyme may also be considered as a potential target for a novel therapeutic approach in
the treatment of solid neoplasms.
Abbreviations: cAMP – cyclic adenosine monophosphate; BCC – basal cell carcinoma; CB – cathepsin B; CD – cathepsin
D; CL – cathepsin L; CNS – central nervous system; CRC – colorectal cancer; EGFR – epidermal growth factor receptor;
GC – gastric cancer; HCC – hepatocellular carcinoma; H&N – head and neck; HIF-1 – hypoxia–inducibile factor 1; IGF –
insulin-like growth factor; IGFBP – insulin-like growth factor binding protein; LSCC – laryngeal squamous cell carcinoma;
MMP-2 – matrix-metalloproteinase-2; MMP-9 – matrix-metalloproteinase-9; NSCLC – non small cell lung cancer; PCNA
– nuclear proliferating antigen; PSA – prostatic specific antigen; SCC – squamous cell carcinoma; SCLC – small cell lung
cancer; TGF-β – transforming growth factor beta; TSH – thyroid stimulating hormone; uPA – urokinase-type plasminogen
activator
Introduction
Structure and biological functions of cathepsin D
Cathepsin D (CD) (EC 3.4.23.5) is a lysosomal acid pro-
teinase which, in the range of pH 2.8–5.0, can degrade
structural and functional proteins, peptides, peptide precurs-
ors and hormones [1–4]. However, it has been shown that
the biological functions of this enzyme are not only con-
fined to the metabolic degradation of intracellular proteins
but also comprise some other important biological processes
(Table 1) [1–17]. In humans, the gene coding for CD has
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been located in chromosome 11p15 and contains 9 exons
[18]. Mice deficient in this gene present alterations in the
small intestine (i.e., necrosis associated with thrombosis of
small vessels) and a large-scale destruction of lymphoid cells
in the spleen and timus [17]. These findings further confirm
the active role of CD in the renewal, remodelling and in ap-
optosis of a wide variety of tissues [1, 5–8, 11, 12, 17]. This
enzyme is synthetized as an inactive 52kDa precursor form
[19]. Its activation is processed intracellularly by sequential
proteolytic cleavage which first involve the removal of the
44-amino-acid propeptide. This cleavage yelds an active 48-
kDa single chain molecule which is then cleaved by cysteine
proteinases into two active chain forms of 34 kDa (heavy
chain) and 14 kDa (light chain) [19]. CD is ubiquitously
present in animal and human tissue, with qualitative and
quantitative differences in its distribution among different
92 G. Leto et al.
organs or cell types of the same organ [1, 4, 11, 12, 14–
16, 20–23]. This uneven distribution seems to be related to
the different biological function carried out by this enzyme
in tissue [1].
Cathepsin D and cancer
CD has also been shown to be widely distributed also in
human tumors. However, many of these tumors present
altered processing, secretion and activity levels of this en-
zyme as compared to normal tissues [4, 22–30]. These
phenomena, which may also be associated with the aggress-
ive behavior of tumors, suggest that CD, in concert with
other proteolytic enzymes involved in the metastatic pro-
cess such as cysteine proteinases cathepsins B (CB) and L
(CL), serine-proteinase urokinase-type plasminogen activ-
ator (uPA) and matrix-metalloproteinases-2 (MMP-2) and
-9 (MMP-9), may promote the malignant progression of
neoplastic diseases [25–36]. The mechanism(s) by which
CD may facilitate this process has still not been fully elu-
cidated. However, in vitro studies carried out mainly on
human breast or ovarian cancer cell lines evidenced that this
proteinase may stimulate tumor cell proliferation, invasion
and metastasis by various mechanism(s) summarized in Fig-
ure 1 (reviewed by Rochefort et al. in [19, 26, 27]). As a
consequence, several studies have been undertaken in order
to evaluate its clinical significance in breast cancer and in
other gynecological neoplasms. These studies showed that,
in node-negative breast cancer patients, CD overexpression
was associated with an increased risk of recurrence and
death [26, 37, 38]. These findings were not confirmed in
male breast cancer, which seems to be biologically differ-
ent from female breast tumor [39, 40]. Conflicting results
were also obtained in other gynecological malignancies [42–
54]. However, these investigations additionally highlighted a
close association between altered expression levels of CD
and the degree of aggressiveness and chemoresistance of
ovarian or endometrial tumors [42–55]. In this context, sev-
eral investigations have also been undertaken to assess the
clinical significance of CD expression in other nongynecolo-
gical solid tumors. Extensive updated reports on the results
of these studies are still lacking in literature. This review
article summarizes these data and discusses their clinical
implications.
Cathepsin D in central nervous system tumors
CD is commonly found in animal and human central nervous
system (CNS) tissue [1, 20, 22–24]. Although its biological
role in CNS is still not well defined, experimental evidence
suggests that this proteinase, along with other proteolytic
enzymes of the apoptotic process, namely caspases [56],
may be involved in the regulation of neuronal cell death,
survival and differentiation [57]. Therefore, altered expres-
sion levels of this enzyme may result in detrimental effects
on the biological and physiological functions of neuronal
cells which may lead to severe degenerative disorders of
CNS such as Alzheimer’s disease or CNS neoplasms [22,
24, 58–62]. This hypothesis is currently supported by several
clinical observations which have shown that, in the human
brain, altered CD levels can be frequently associated with
these diseases [21–23, 57–62]. The mechanism(s) by which
CD may promote the progression of CNS tumors are still
unknown. However, certain in vitro studies showed that anti-
CD antibodies, in a dose-dependent fashion, significantly
reduced the invasive potential of human glioblastoma cells.
These findings indicated that this proteinase may facilitate
the adhesion and the subsequent invasion of these tumor
cells to the extracellular matrix of host tissue [63, 64]. The
potential role of CD in the modulation of the invasive activity
of CNS tumors has been further supported by some im-
munohistochemical investigations which demonstrated that
the invading cells of astrocytomas, glioblastomas, oligo-
dendrogliomas and mixed gliomas expressed CD, MMP-2
and MMP-9, and that the switching to an invasive pheno-
type of these tumors was followed by an increase in CD
expression levels [64]. More recently, Castino et al. [65]
have hypothesized that this proteinase, in association with
CB, can modulate some proteolytic occurrences of caspase-
dependent apoptosis which are essential for neuroblastoma
cell survival. This may, in part, explain the cytotoxic effect
induced by pepstatin A, a naturally occurring inhibitor of
CD, on neuroblastoma cells after a 72-h incubation period
[65, 66]. These findings further showed that CD may act at
different steps of the growth of CNS neoplasms and sugges-
ted a potential clinical role of this proteinase as an indicator
of aggressiveness and prognosis of these tumors. However,
little research has been undertaken so far to test this hypo-
thesis. Some biochemical studies have shown, at least in
human gliomas, a close relationship between up-regulation
of this enzyme and malignant progression of this tumor [63].
Recently, Castilla et al. [62] reported a significant associ-
ation between an increased immunocytochemical expression
of CD in meningiomas and recurrence, whereas no correla-
tion with patients’ outcome was noted. These observations
indicate that the evaluation of CD expression may be use-
ful in identifying more aggressive forms of CNS neoplasms,
and may be seen as an attractive target for innovative thera-
peutic approaches to these tumors [63–65]. However, due
to the lack of extensive clinical studies, its prognostic value
remains to be determined.
Cathepsin D in head and neck tumors
Immunohistochemical and immunoenzymatic studies have
shown that CD expression levels may be found to be altered
in different tumors of the head and neck (H&N) includ-
ing those of the oral cavity, parotid gland, salivary glands,
oro- and hypo-pharinx and larynx [67–73]. The biological
significance of such alterations has still not been properly
understood. However, there is a lot of experimental and clin-
ical evidence to suggest that this phenomenon may be related
to the dissemination of H&N neoplasms, and ultimately to
the onset of more aggressive forms of these tumors [68–
75]. This latter observation is further supported by recent
in vitro studies which have shown that, in human laryngeal
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Table 1. Main biological functions in which cathepsin D appears to be involved.
Reference number
Metabolic degradation of intracellular proteins [1]
Processing, activation and degradation of polypeptide hormones, growth factors and receptors [1–4]
Biological regulation of programmed cell death [5–10]
Tissue remodelling and renewal [1, 11, 12, 17]
Activation of latent precursor forms of other proteolytic enzymes [13]
Activation of neutrophils and leukocytes [14, 15]
Monocyte-mediated fibrinolysis [16]
Figure 1. Step 1. Cathepsin D may promote tumor cell proliferation: a) by acting as an autocrine mitogen through the interaction with a transmembrane
receptors (?) [19, 26, 34, 35, 140, 141]; b) by activating growth factors [19, 26, 34, 35]; c) by degrading growth factors inhibitors [36]; d) by interacting
with growth factor receptors [19, 26, 27, 138–141]; e) by affecting the apoptotic process [5, 34, 36, 57, 65, 113–115]. Step 2. Cathepsin D may directly
degrade extracellular matrix (ECM) and facilitate tumor cell invasion [19, 25, 26, 63]: 2a) this phenomenon may additionally induce the release of
biologically active forms of growth factors preincorporated in the ECM which, in turn, may stimulate tumor cells to proliferate [19, 26]. Step 3. Cathepsin
D may trigger off a proteolytic cascade, by activating latent precursor forms of other proteolytic enzymes and chemiotactic factors which may facilitate
ECM degradation, invasion, angiogenesis and metastasis formation [13, 24-26, 35, 102, 116, 127, 161, 170]. ∗MMPs – matrix-metalloproteinases; uPA –
urokinase-type plasminogen activator; ECM – extracellular matrix
carcinoma (LSSC) cell lines, increased intracellular levels
of CD and uPA, were associated with the onset of resistance
to different classes of antitumor agents such as doxorubi-
cin, cis-platinum and vincristine [76]. The mechanisms by
which CD may induce the progression H&N tumors remain
to be clarified. However, clinical evidences suggest that CD
may well aid the early phases in this process by facilitating
the proliferation, adhesion and local dissemination of tumor
cells. In fact, immunohistochemical studies by Goussa et
al. [72] on 39 tissue samples from invasive LSCC showed
a significant correlation between the expression levels of
CD and the hyaluronic acid receptor CD44 whereas, in 97
patients with oral cancer, Vigneswaran et al. [73] observed
a significant association between increased CD expression
and proliferation rate, histological grade and presence of
metastasis. Moreover, Kawasaki et al. [74] recently demon-
strated in 78 patients with oral squamous cell carcinoma
(SCC), a close relationship between the CD expression and
the pattern of invasion, clinical stage, nodal status, nuclear
proliferating antigen (PCNA) and shorter survival time. The
hypothesis that CD may play a role in the early phases of
H&N cancer progression has been further corroborated by
some of our recent clinical observations, which showed that,
unlike in early clinical stage (I/II) LSCC, CD levels were
not increased in locally advanced tumors (stage III/V) as
compared to normal adjacent mucosa [67, 77]. In addition,
our data also highlighted significantly higher uPA levels in
tumor tissues when compared to its normal counterpart [77].
A comparative analysis of the distribution of CD and uPA
in stage III/IV LSCC showed that CD was more noticeably
expressed only in tumors with a high proliferation rate, as
compared to those with a low proliferation index, whereas
uPA was more noticeably expressed in node-positive tu-
mors than in node-negative tumors, in stage-IV tumors than
stage-III tumors and in aneuploid multiclonal tumors than in
aneuploid-monoclonal or diploid tumors. [77]. These results
further indicated that, at least in the case of LSCC pro-
gression, CD seems more likely to be involved in tumor
cell proliferation and local growth whereas uPA seemed to
be implicated in subsequent events in this process such as
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the invasion and further dissemination of tumor cells. Al-
though these findings might suggest a prognostic role for
CD in LSCC, conflicting results have emerged from studies
aimed at evaluating this hypothesis. Immunohistochemical
investigations by Resnick et al. [78] on 88 LSCC patients
did not find any significant relationship between CD ex-
pression, degree of nodal involvement, disease-free survival
or overall survival time. Similar studies by Seiwerth et al.
[79] in 61 untreated LSCC patients, in part, confirmed these
findings. However, these authors reported a significant cor-
relation between CD immunoreactivity in both epithelial and
stromal cells and patient survival. On the other hand, Lazaris
et al. [80] observed by immunocytochemistry that, among 64
LSCC patients, those with CD positive lymph nodes were
at higher risk of relapse. The positive relationship between
CD expression and nodal involvement was further confirmed
by the immunoradiometric studies of Maurizi et al. [81] on
63 patients with primary LSCC. In addition these authors
showed that, at the cut-off level considered (13.8 pmol/mg
of protein), CD tumor content significantly correlated also
with metastasis-free survival and overall survival. However,
other immunoradiometric or immunoenzymatic studies, in-
cluding our own investigations, failed to find any correlation
between CD tumor levels and the biological and clinical
parameters of progression or patients’ survival [77, 82]. The
discrepancies in these results may be, in part, explained by
the different assay methods and/or antibody used and/or by
the cut-off limits considered. However, it also cannot be
ruled out that the different criteria of selection, the num-
ber of patients, the different anatomical site considered and
the different follow-up periods may also account for these
conflicting results. Although the prognostic significance of
CD remains controversial, evidence emerging from these
studies suggests that this proteinase may be useful as as a
biological marker for identifying patients with primary tu-
mor at increased risk of recurrence and onset of resistence
to therapeutic treatment. Further studies with standardized
techniques may better define the clinical role of CD in H&N
cancer.
Cathepsin D in thyroid tumors
In the human thyroid gland CD is one of the proteolytic en-
zymes involved in the metabolism of thyreoglobulin [3, 4].
In some pathological conditions, such as Graves’ disease and
toxic adenoma, increased activity or content levels of this
proteinase have been shown to be associated with a hyper-
functional thyroid [4, 83]. This phenomenon appears to be
induced by TSH as these pathological conditions are related
to a permanently stimulated cAMP transduction pathway
which mediates the effects of TSH on thyroid cells including
the synthesis and secretion of CD [4, 84, 85]. Therefore, a
number of investigations have also been carried out to as-
sess the clinical significance of CD expression in thyroid
tumors. Early biochemical studies by Sinadinovic et al. [86]
reported that the patients’ papillary thyroid carcinoma tis-
sue presented an enhanced proteolytic activity of lysosomal
acid proteases as compared to normal thyroid tissue. The
authors speculated that this phenomenon was probably the
result of metabolic disturbances in the catabolic degradation
of thyreoglobulin in tumor tissue. Further immunoenzymatic
investigations by Métayé et al. [83] carried out on a small
number of patients (n = 12) showed that CD content
levels were significantly higher in thyroid carcinoma, toxic
adenoma or Graves’ disease, than in normal tissue or be-
nign nodules. However, no difference was observed between
thyroid carcinoma and Graves’ disease or toxic adenoma. In-
terestingly, these studies and later investigations of the same
group carried out on 34 patients evidenced a significant asso-
ciation between CD levels in primary tumors and tumor size
[83, 87]. Additional observations of these authors showed
that the activity levels of this enzyme in different human
thyroid tissues were 3.0, 2.3 and 1.3 times higher in cancer
tissue or toxic adenoma, in Graves’disease, and in cold be-
nign nodule respectively, than in normal thyroid tissue [4]. In
addition, in a small number of samples, it was also noted that
mean CD activity levels were higher in anaplastic carcino-
mas than in well differentiated thyroid carcinomas [4]. These
findings indicated the existence of a possible correlation
between degree of CD expression and aggressive behavior
of thyroid tumors, and suggested that CD could play a role
in their propensity to metastasize. This hypothesis was sup-
ported by some studies by Ruhoy et al. [88], who showed
that CD immunostaining was higher in follicular carcino-
mas than in follicular adenomas and that this phenomenon
was greatest in extensively invasive follicular carcinomas.
These observations suggested that this proteinase could be
of clinical interest as a prognostic marker in thyroid tumors
[83, 88]. To date, however, no extensive clinical studies to
assess this hypothesis have yet been undertaken. A single
study on 44 patients with medullary carcinoma reported
a weak correlation between the immunohistochemical ex-
pression of CD and poor prognosis [89]. Thus, additional
clinical investigations to establish the prognostic signific-
ance of this enzyme are needed. However, the results of the
existing studies indicated that CD may be useful as a specific
marker to identify tumors endowed with a greater invasive
and metastatic potential. This findings may greatly improve
the therapeutic approach and the prognosis of these tumors.
Cathepsin D in lung cancer
The role of CD and its clinical significance in lung cancer is
still controversial. Some biochemical and immunoenzymatic
studies have questioned its direct involvement in the growth
and advance of at least of some histological types of lung
cancer. For instance, Ledakis et al. [90] reported that, in
non-small-cell lung cancer (NSCLC), CD activity or content
levels, had not increased, unlike CB and CL, as compared
with adjacent normal lung tissue. Moreover, other immuno-
histochemical studies by Fontanini et al. [91] undertaken on
108 NSCLC patients showed that, CD expression levels was
associated with smaller size (< 3 cm), less advanced tumors
(T1), more differentated (G1-2) tumors and non-squamous
histotypes. In addition, in non-squamous histotypes, CD im-
munoreactivity was associated with early staged (S1) and
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lymph node-negative (N0) tumors whereas no correlation
was observed with proliferation indices such as DNA ploidy,
S-phase fraction, PCNA or Ki-67. On the contrary, studies
on patients with small cell lung cancer (SCLC) evidenced
that a low staining for CD or its absence was associated with
a prolonged survival [92]. Moreover, Higashiyama et al.
[93] observed that, in patients with stage I lung adenocar-
cinoma, the subcellular localization of CD in the basal or
infranuclear side of the cytoplasm in tumor cells, as well as
its presence in stromal cells within the tumor tissues, was
associated with a worse prognosis. These results sugges-
ted that CD may play a differential role in the regulation
of the growth and differentiation of various histological
types of lung cancer. As a consequence, its prognostic im-
pact in these neoplasms might be strongly affected by the
histological type of the tumor and/or its status in stromal
cells. Therefore, the clinical significance of CD expression
in different histotypes of lung cancer needs to be better
defined through precisely conceived studies and standard-
ized immunohistochemical methods. Furthermore, studies
have been recently undertaken to evaluate the clinical utility
of serum-CD activity levels in the therapeutic monitoring of
lung cancer patients [94]. These investigations, carried out
on 21 patients with stage-II/III SCLC, showed that the activ-
ity levels of this enzyme were significanty higher in SCLC
patients than in healthy subjects. These levels markedly de-
clined after surgery albeit remained three times higher than
those determined in the control group [94]. These observa-
tions suggested that serum CD activity may be potentially
useful for the therapeutic monitoring of lung cancer patients
undergoing surgical and/or clinical treatments. However, ex-
tensive clinical studies with a larger number of patients are
needed to assess this hypothesis.
Cathepsin D in tumors of the gastrointestinal tract
Gastric cancer
Immunohistochemical analysis of CD distribution in gastric
tissues has shown that this proteinase is widely present in
different cell types of normal gastric mucosa, as well as in
benign and malignant gastric diseases [21, 95–103]. How-
ever, its specific role in the malignant progression of gastric
cancer (GC) has still not been clarified. Early immunocyto-
chemical studies did not evidence any significant difference
in the distribution of this proteinase between normal mucosa
and inflammatory gastric diseases [95]. Moreover, these
studies showed the absence of any immunoreactivity to CD
in intestinal metaplasia or dysplasia or in well differenti-
ated gastric adenocarcinoma. However, a strong and diffuse
staining for CD was observed in poorly differentiated ad-
enocarcinomas and in signet ring cell carcinoma [95]. These
findings suggested a correlation between CD expression
levels and degree of differentiation of gastric cancer but did
not clarify whether this enzyme might have a specific role in
the progression of this tumor. However, clinical observation
supports the hypothesis that CD may play a key role in this
process, probably, by facilitating tumor cell invasion. In fact,
some immunohistochemical studies have described a differ-
ential immunostaining pattern of CD expression in primary
gastric carcinoma tissue [96]. The most intense staining was
noted in tumor cells at the advancing margin of the tumor.
This peculiar localization was significantly correlated with
certain clinical parameters of GC progression, such as the
clinical stage and occurrence of lymph-node metastasis [96].
Other biochemical and immunohistochemical studies further
confirmed the relationship between CD activity and the in-
vasive potential of GC [97, 98]. Therefore, several clinical
investigations were carried out to evaluate the clinical signi-
ficance of this proteinase, mainly in patients with curatively
resected cancer, that was at risk of recurrence. Immunohisto-
chemical studies by Allgayer et al. [99] on 203 consecutive
patients showed that CD expression levels were significantly
associated with overall survival and a shorter disease-free in-
terval. Multivariate analysis identified CD as an independent
parameter for disease-free interval [99]. In contrast, some
of our immunoenzymatic studies undertaken on 57 patients
with operable GC showed, that CD levels in GC tissue,
unlike CB and CL, did not increase as compared to paired
normal gastric mucosa nor did they correlate with some of
the clinicobiological parameters of progression of this tu-
mor including the patients’ outcome [100]. It is likely that
the different methods and antibodies used, and/or the differ-
ent number of patients investigated may account for these
conflicting results. On the other hand, some recent immuno-
histochemical studies by Goishi et al. [101] showed that, in
136 patients with tumors invading the submucosa and mus-
cularis propria, CD expression correlated significantly with
the increasing incidence of lymph-node metastasis. These
observations were in agreement with those of Ikeguchi et al.
[102] who showed, in 160 patients with early GC, a sig-
nificant correlation between CD expression and occurrence
of micro-lymph-node metastasis. Further observation by the
same group of a larger number of patients (n = 478) evid-
enced that the percentage of CD-positive cancer cells was
higher in diffuse-type carcinoma than in intestinal-type car-
cinoma [103]. These findings were also confirmed by the
immunoenzymatic studies of Garcia et al. [104]. Further-
more, Ikeguchi et al. [103] reported that, in both diffuse
and intestinal type of carcinoma, CD expression levels were
associated with depth of tumor invasion and a worse disease-
specific five-year survival rate whereas CD levels in stromal
cells were associated with either depth of invasion or with
a worse five-year survival rate only in the intestinal type
carcinoma [103]. These findings indicated that the CD of
stromal cells seems to play an active role in the invasion of
this type of tumor and suggested that it may strongly influ-
ence the prognostic significance of this enzyme. Although
these studies did not fully clarify the mechanisms by which
CD may induce the growth and spread of GC, they provided
evidence for the clinical utility of CD as a marker of lymph
node involvement and indicate that this proteinase may be
a good candidate as prognostic parameter for predicting the
clinical outcome of GC patients.
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Colorectal cancer
Several investigations have shown that CD levels may be
found to be altered in colorectal cancer (CRC) and that this
phenomenon is frequently associated with CRC progression
(105–112). These data indicate that CD may have a role in
the growth and spread of CRC. However, the mechanisms
by which CD may facilitate this process are not well un-
derstood. In vitro studies showed that HT-29 human colon
carcinoma cell lines presented an altered secretion of CD
which was associated with a less differentiated state of these
cells [113]. This phenomenon, which appears to facilitate
the degradation of the extracellular matrix by tumor cells,
seems to be related to altered levels of cell associated cer-
amide, an important mediator of the apoptotic process [114,
115]. As CD seems to be involved in the biological regu-
lation of programmed cell death [5–10, 57, 65, 113–115]
it is conceivable that its altered secretion may also result
in disturbances of the normal apoptotic process which may
facilitate tumor cell growth. However, other experimental
observation showed that CD may induce the growth and
spread of this tumor by other mechanisms such as the activ-
ation of latent precursor forms of other proteinases involved
in the metastatic process. This latter hypothesis is supported
by some studies of van der Stappen et al. [13] who ob-
served that, in an in vitro model of CRC progression, the
conversion of non tumorigenic adenoma derived cell lines
to a highly tumorigenic phenotype was associated with an
eight-fold increase of pro-CB and to an enhanced secretion
of CD. Moreover, these studies also evidenced that the ac-
tivation of CB was mediated by CD. This phenomenon may,
in turn, trigger off the proteolytic cascade which leads to
the degradation of extracellular matrix and the subsequent
invasion of host tissues by malignant cells (Figure 1). The
potential involvement of CD in CRC invasion has been fur-
ther sustained by recent observation which has shown that,
in human HCT116 colon carcinoma cells, the overexpres-
sion of hypoxia-inducibile factor 1 (HIF-1) stimulates the
expression of genes encoding for several factors, includ-
ing CD, which contribute to extracellular-matrix invasion
[116]. These experimental findings suggest that CD may
have a potential clinical role as marker of aggressiveness
and poor prognosis in CRC patients. Several clinical stud-
ies have been performed to assess this hypothesis. Our early
investigations on 68 matched paired sets of CRC and normal
tissue sample homogenates showed significantly increased
CD activity levels in tumor tissues as compared to adja-
cent paired normal mucosa and it was demonstrated for
the first time that this activity was significantly higher in
early clinical stage CRC (i.e., Dukes’ stage A) than in later
clinical stages (i.e, Dukes’ B, C and D) [105]. These lat-
ter observations, which further indicated an involvement of
CD in the early stages of CRC growth and progression,
were not confirmed by subsequent studies from other au-
thors [106]. These discrepant results might be due to the
different number of patients considered. On the contrary,
our later immunoenzymatic studies on 21 matched paired
CRC and normal mucosa samples did not evidence any sig-
nificant difference in CD content between tumor and paired
normal tissue [107]. However, unlike the described enzyme
activity, a significant correlation was observed between CD
tumor content and tumor size or grade [107]. These findings
further underline that different results may be obtained in
accordance to the methodological approaches and/or number
of patients used. For instance immunohistochemical analysis
of CD expression carried out by Theodoropoulos et al. [108]
on 60 surgical CRC samples showed that the presence of
CD immunoreactivity in stromal cells was associated with a
more invasive phenotype, while Kanber et al. [109] showed
that stromal CD expression was also related to tumor stage.
On the other hand, Arao et al. [110] reported that the immun-
ostaining pattern of CD in tumor cells, but not the incidence
of CD positive tumors, was associated significantly with
lymphatic invasion. Furthermore, Oh-e et al. [111], follow-
ing the immunocytochemical evaluation of the intracellular
pattern of expression of CD in 254 invasive CRC, observed
a significant correlation between this parameter or positive
expression of CD in stromal cells, and incidence of lymph-
node metastasis. These findings indicate that, as previously
described for GC, CD stromal cells appear to influence the
invasive potential of CRC tumors. Therefore, analysis of
CD expression in both tumor and stromal cells can be re-
garded as a useful predictor for lymph-node metastasis, and
consequently, may have a clinical relevance in predicting
the clinical outcome of CRC patients. These observations
indicate that the immnunohistochemical evaluation of CD
expression is more reliable than other methods for investig-
ating the clinical significance of this proteinase in CRC. In
conclusion, experimental and clinical findings indicate that
CD appears to promote the progression of CRC, probably
by affecting the apoptotic process of tumor cells and/or by
facilitating tumor cell invasion, and that this enzyme may
be clinically relevant as a predictive marker of lymph-node
involvement and poor clinical outcome in CRC patients.
Liver cancer
Several experimental and clinical studies support the hypo-
thesis that CD may also be implicated in the onset and pro-
gression of liver tumors. For instance, in vitro and in vivo ob-
servations evidenced that the extremely fast-growing Morris
hepatoma 777 cells presented altered, intracellular pro-
cessing and increased secretion of a precursor form of CD
whereas the ascitic fluid and the plasma of rats transplanted
with Yoshida AH-130 hepatoma presented elevated levels of
CD activity [118, 119]. Interestingly, increased CD activ-
ity levels were also observed in human hepatoma tissues
as compared to its normal counterpart [120]. These experi-
mental observations were further confirmed by clinical find-
ings, which showed that CD activity or content levels were
significantly elevated in sera of patients with chronic liver
diseases, such as active hepatitis, cirrhosis and/or hepato-
cellular carcinoma (HCC), as compared to healthy subjects
[121–124]. These findings suggest an active involvement of
CD in the malignant progression of liver tumors. Experi-
mental studies undertaken to investigate the mechanisms by
which CD may trigger this pathological process suggested
that this proteolytic enzyme seems to facilitate the prolifera-
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tion and dissemination of hepatic tumor cells. In fact, some
in vivo studies in mice showed that intraperitoneal injections
of purified preparation of CD stimulated DNA synthesis and
mitosis in the intact liver of these mice [125, 126]. As CD
seems to promote in vitro tumor cell proliferation, it can be
hypothesized that this proteinase may stimulate tumor cells
to proliferate through its mitogenic activity [19, 26]. How-
ever, experimental evidence to support this hypothesis has
not yet been forthcoming. Furthermore, other in vitro studies
showed that human hepatoma cell line PLC/PRF/5 actively
secretes CD in addition to transforming growth factor β
(TGF-β) and fibronectin [127]. The authors of these studies
speculated that the secreted CD may activate latent forms of
TGF-β which, in turn, regulates the secretion of fibronectin,
a strong inducer of chemiotaxis. These events may lead to
a further migration and invasion of surrounding tissues by
tumor cells. However, in this case too, experimental and
clinical evidences which supports this mechanism are still
lacking. The hypothesis that CD may play an active role in
the onset and progression of liver tumors have led several
studies to assess its clinical significance in these tumors as
well as in some premalignant liver diseases such as cirrhosis.
Our studies and those of Brouillet et al. [123, 124] showed
that, in patients with cirrhosis, CD antigen levels were sig-
nificantly higher than those determined in HCC patients. In
addition, our data also showed that patients with steatosis
had significantly higher CD serum levels as compared to
healthy subjects, but these levels were significantly lower
than those measured in patients with liver cirrhosis and/or
HCC [124]. These findings and other experimental data in-
dicated that CD, in concert with other proteolytic enzymes,
could be involved in the process of tissue remodelling which
occurs during the evolution of cirrhosis [121, 128–130]. As
this process may be associated with the malignant trans-
formation of liver tissue, it can be speculated that CD may
contribute also to the onset of malignant lesions in cirrhotic
tissue [123, 124, 131]. These observations suggest that CD
may be potentially useful as a biochemical marker for identi-
fying those patient with cirrhosis who risk developing HCC.
On the other hand its prognostic value in these tumors re-
mains to be assessed. Unfortunately, to date few clinical
studies have been carried out toward this aim. A recent im-
munohistochemical study on 85 HCC patients showed that
CD expression, was correlated with the histological grade
but the prognostic value of this enzyme to predict the clinical
outcome for these patients was not assessed [132].
Pancreatic cancer
There are not very many studies into the role, and the clinical
significance, of CD in pancreatic cancer. In 1986 Yamaguchi
and Kawai [133] first reported that human pancreatic tumor
cell line HPC-YT actively secreted in vitro a ‘Cathepsin-
D-like enzyme’ which was different from that present in
normal pancreas. The authors suggested that this form might
be responsible for the degradation of the host extracellular
matrix and that it might facilitate the invasion of this tu-
mor. However, no further studies to confirm this hypothesis
have been carried out. On the basis of these observations we
tried to assess the clinical significance of the serum levels
of CD, and also of CB and CL in patients with pancreatic
carcinoma or pancreatitis. Our results showed that in cancer
patients, unlike observed for CB and CL, CD serum levels
were lower than those measured in normal subjects nor were
the enzyme levels correlated with any of the biological and
clinical parameters of progression of this tumor [134]. These
findings confirmed previous immunocytochemical observa-
tions by Nakata et al. [135], who demonstrated a lack of
correlation between CD expression in pancreatic tumor cells
and the presence of metastatic foci in lymph nodes and in
other organs. However, our data also showed that CD serum
concentrations were significantly more elevated in patients
with acute or chronic pancreatitis as compared to healthy
subjects or cancer patients [134]. This phenomenon was
noted also for CB, but not for CL. These observations indic-
ate that CB and CL might well appear to be more relevant
than CD as prognostic markers in pancreatic cancer. This
hypothesis was recently confirmed by immunohistochem-
ical studies by Niedergethmann et al. [136] who reported
a significant correlation between the expression levels of
these proteinases and an unfavorable clinical outcome in pa-
tients with operable pancreatic cancer. These findings seem
to rule out a direct role for CD in the progression of pan-
creatic cancer. However, the different serum pattern of this
proteinase in pancreatic cancer and pancreatitis might be a
useful additional parameter in the differential diagnosis of
these diseases.
Cathepsin D in tumors of the genitourinary tract
Prostatic cancer
At present the role of CD in prostatic cancer is not well
known. However, experimental evidence indicates that this
proteinase may likely stimulate the growth of this tumor by
interacting with hormone receptors or growth factor recept-
ors and/or through its mitogenic activity. In fact, in vitro
studies suggested that CD seems to facilitate the prolifera-
tion of prostatic tumor cells induced by insulin-like growth
factor (IGF), by proteolytic degradation of IGF-binding pro-
teins (IGFB) or, in the case of androgen-dependent tumor
cells, by hydrolizing androgen receptors [137–139]. Inter-
estingly, this latter phenomenon did not occur in normal
prostatic tissue. On the other hand, Vétvic´ka et al. [140]
showed that several human prostatic cancer cells secreted
an enzymatically inactive pro-CD, containing an activation
peptide localized in the N-terminal amino-acid region 27–
44, which induces tumor cell proliferation and motility,
probably, by interacting with an unknown transmembrane
receptor [140, 141]. This hypothesis was corroborated by
some experimental in vivo observations which demonstrated
that the administration of anti-27–44 peptide antibodies to
nude mice transplanted with LNCaP human prostatic can-
cer cells or MDA-MB-231 breast cancer cells inhibited the
growth of these tumors [140, 141]. However, Konno et al.
[142] showed that the antibiotic brefeldin A inhibited in vitro
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Table 2. Clinical significance of cathepsin D expression in nongynecological solid tumors.




Neuroblastomas 24 IHC 13 G NA
Meningiomas 62 IHC 86 G DFS
Gliomas 64 IHC 45 I NA
Head and neck
Different 69 IRMA 53 No NA
anatomical sytes 70 IRMA 92 No NA
71 IRMA 111 G NA
75 IHC 34 N NA
Salivary gland 68 IHC 44 Histological type NA
Oral cavity 73 IHC 97 P, G, M NA
74 IHC 78 N, S, I, PCNA OS
75 IHC 34 N NA
Laryngeal SCC 77 EIA 57 No No
78 IHC 88 No No
79 IHC 61 No OS
80 IHC 64 No DSF
81 IRMA 63 N DFS, OS
Thyroid
4 EA/IHC 107 G NA
83 IRMA 14 T NA
87 IRMA 32 T NA
88 IHC 34 G NA
89 IHC 44 S No
Lung
91 IHC 108 (NSCLC) T, N, G, Sd NA
92 IHC 13 (SCLC) No OSd
93 IHC 152 (AdenoK, Stage I) Number of scars OS
Gastrointestinal tract
Oesophageal SCC 182 IHC 154 I, p53, Ki-67 No
Gastric 95 IHC 21 G –
96 IHC 44 N, S NA
97 EA 42 I, N, G NA
98 IHC 29 + 15 adenomas I, N NA
99 IHC 203 G OS
100 EIA 57 No No
101 IHC 136 N NA
102 IHC 160 N No
103 IHC 478 I OS
Colorectal 105 EA 68 Sd NA
106 EA 27 No NA
107 EIA 21 T, G NA
108 IHC 60 I, S OS
109 IHC 34 + 24 adenomas I NA
110 IHC 254 G, I, N NA
111 IHC 31 + 29 adenomas S NA
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Table 2. Continued.
Tumor Reference Assay methodsa No. of patients Correlation with
Clinicopathologicalb Survivalc
parameters
Liver 123 IRMA/ serum 27 No NA
124 EIA/ serum 56 No NA
132 IHC 85 G NA
Pancreas 134 EIA serum 22 No NA
135 IHC 21 No No
Genitourinary tract
Prostate 146 EIA 20 No NA
147 IRMA 15 No NA
148 IHC 69 S NA
149 IHC 102 Gleason score NA
150 IHC 61 Gleason, ploidy NA
151 IHC 105 No No
152 IHC 71 No No
153 EIA/densitye 80 S, M No
154 EIA 72 I, S, M NA
Bladder 155 IHC 77 Rb, CD44, Gd, Sd, P53d NA
156 IHC 105 G, Sd DFSd, OSd
157 IHC 60 G, Sd DFSd
158 IHC 177 G, I, EGRF, P53, S-phase OS
159 IHC 20 (T1) No No
160 IRMA 93 No No
161 IHC 32 No No
167 IHC/Western blot 23 I No
Melanoma and other skin tumors
Melanoma 169 IRMA 51 NA DFS
171 IHC 147 I DFS
172 EIA/plasma 108 Md No
SCC, BCC, Bowen disease 173 IHC 46 I NA
SCC 174 IHC 53 I, M DFS
aIHC – immunohistochemistry; IRMA – radioimmunoassay; EIA – enzyme immunoassay; EA – enzyme activity.
bT – tumor size; G – tumor grade; N – nodal involvement; S – stage; M – metastasis; P – proliferation rate; I – depth of invasion.
cDFS disease-free survival; OS – overall survival; NA – not assessed.
dInversely correlated with cathepsin D expression.
eCathepsin D density: ratio Cathepsin D serum content/prostate volume.
the proliferation of LNCaP, PC-3 and DU-145 human pro-
static cancer cells. These effects, which were more marked
in LNCaP cells, were associated with an overexpression of
pro-CD induced by a blocking of maturation (i.e., activa-
tion) of CD caused by this antibiotic. These results seem to
be in contrast with those reporting a stimulating effects of
pro-CD on proliferation of breast or prostatic cancer cells.
However, as LNCaP are androgen-dependent cancer cells,
and brefeldin A has been shown to induce a dramatic re-
duction (> 90%) in the level of expression of androgen
receptors [143], it might conceivably be hypothesized that
the inhibiting effects of this antibiotic on cell growth are the
consequence of a down-regulation of these receptors which
may also mediate the proliferating effects of pro-CD. On the
other hand, the inhibiting effects of brefeldin A on androgen-
indipendent PC-3 and DU-145 prostatic tumor cells seemed
to be induced by different mechanisms involving the cell-
cycle regulatory retinoblastoma protein (pRB) and cyclin-
dependent kinase inhibitor WAF1 (p21) respectively [142].
These findings suggest that CD may have a differential role
in modulating the growth of androgen-dependent and inde-
pendent prostatic cancer cells. This hypothesis is supported
by recent in vitro studies which show that pro-CD secreted
by androgen-independent PC-3 human prostatic carcinoma
cell lines, following its conversion to pseudo-CD, could
generate angiostatin from plasminogen and that this phe-
nomenon might prevent angiogenesis-dependent growth of
the metastasis [144]. However, evident proof that CD may
modulate also in vivo the growth of prostatic cancer by these
mechanisms is still lacking. On the other hand, clinical stud-
ies aimed at assessing the role and the prognostic impact of
this enzyme in prostatic cancer have generated conflicting
results, according also to the method used. Immunoblot ana-
lysis by Cherry et al. [145] reported that human prostatic
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cancer tissue expressed a mature form of CD, with a higher
catalytic activity, whereas normal or benign prostatic hyper-
plasia predominantly expressed an inactive precursor form
of the enzyme. However, immunoenzymatic studies by Yang
et al. [146] which analyzed the distribution of CD in the
cytosol fractions of 22 samples of hyperplastic tissue and 20
of prostate cancer tissue, showed no difference in enzyme
content between these tissues nor any correlation between
CD tumor levels and other clinicobiological parameters such
as degree of differentiation and expression of sex hormones
while other prognostic parameters were not considered. On
the contrary, immunoradiometric studies by Chambon et al.
[147] on 15 human prostate cancer tissue samples showed
that cystosolic CD concentrations were more elevated in tu-
mor tissues than in normal prostate or prostatic hyperplasia.
However, when the authors further analyzed by immuno-
histochemistry, the distribution of CD in these tissues, they
observed, according to their score system, a higher expres-
sion of CD in benign prostatic hyperplasia [147]. On the
other hand, other immunohistochemical studies by Makar
et al. [148] on 69 cases of primary adenocarcinoma of the
prostate showed, according to the score method reported by
these authors, a significant correlation with the pathological
stage but not with the Gleason grade. Unlike these observa-
tions, later studies by Maygarden et al. [149] showed in a
larger number of patients (n = 102) a significant correla-
tion between CD expression and Gleason’s combined score.
Furthermore, quantitative immunohistochemical studies by
Ross et al. [150] on 61 prostatic carcinoma biopsies further
confirmed this latter finding. In addition, these authors also
demonstrated a significant correlation between CD expres-
sion and DNA-ploidy, but not with serum prostate specific
antigen (PSA) levels, pathological stage or post resection
disease recurrence [151]. The failure of CD to the pre-
dict clinical outcome for patients with clinically localized
prostatic carcinoma was further supported by other immun-
ohistochemical studies [151, 152]. These findings suggest
that in prostatic cancer CD appeared to be of clinical rel-
evance as an indicator of disease progression but not as a
prognostic parameter. This hypothesis has been corroborated
by recent immunoenzymatic studies by Hara et al. [153]
who have shown that serum CD and its density (i.e., ratio
CD serum levels/prostate volume) were significantly higher
in patients with metastatic disease as compared to those
without metastasis. However, either CD serum levels, or its
density did not significantly correlate with patients’ survival
rate. Moreover, Miyake et al. [154] have recently observed
that serum CD combined with systemic biopsy and/or PSA
levels may be useful as predictive marker of extraprostatic
extension of the tumor in patients who have undergone rad-
ical prostatectomy. These results indicated that CD may be
an additional marker to identify patients with more aggress-
ive forms of prostatic cancer needing specific therapeutic
treatment. However, the use of well standardized method-
ologies are needed to better assess the clinical role of CD in
the management of this tumor.
Bladder cancer
The pattern of CD expression in normal and pathological
bladder tissue and its clinical significance in bladder can-
cer has been extensively investigated mainly by immuno-
histochemical methods [21, 155, 156]. Early studies by
Dickinson et al. [156] on 105 samples of transitional blad-
der carcinoma showed that CD was expressed in 100% of
normal urothelium whereas only 51% of tumors were CD
positive. In addition, these studies evidenced a significant
inverse correlation between CD expression and tumor mor-
phology, tumor stage or grade whereas no correlation with
DNA ploidy was observed. Univariate analysis showed that
negative staining for CD was associated with a poor pro-
gnosis, while multivariate analysis failed to demonstrate
any correlation between CD expression and overall sur-
vival. These results tallied with other immunohistochemical
studies which reported an inverse correlation between CD
score and tumor grade [157]. Furthermore, these studies
showed that patients with a high PCNA labelling index and
CD-negative tumors had a significantly poorer prognosis
compared to those with a low PCNA index and highly CD-
positive group while multivariate analysis indicated that both
these parameters were not independent prognostic factors
[157]. Therefore, CD was considered a useful tool for identi-
fying the malignant potential of bladder transitional cell
carcinoma, and may provide additional information for pre-
dicting survival when stratifying for tumor grade. In this
context, immunohistochemical studies by Lipponen [158]
on 177 patients reported that the strong expression of CD
detected in 40% of bladder tumor specimens was associated
with tumor grade 2–3, S-phase fraction, muscle invasive
growth and overexpression of EGFR. These findings, in part,
clash with the previous ones. These conflicting data may
partially be explained by the different number of patients
considered. Interestingly, this author also showed that CD
was expressed in macrophage-like cells at the invasion front
of the tumor which were infiltrated by inflammatory cells
and tumor cells overexpressing EGFR or p53 protein. Mul-
tivariate analysis showed that the presence of CD-positive
tissue macrophage, in addition to other variables, was an
independent prognostic factor. These studies indicated that,
similarly as reported for other neoplasms, stromal CD, may
have a role in modulating the invasive activity of this tumor
and may influence its prognostic significance. On the con-
trary, Ozer et al. [159] did not find any prognostic value
of CD immunostaining in 20 patients with high-grade T1-
stage primary bladder cancer. Furthermore, imunoenzymatic
studies by Salman et al. [160] reported that CD content
levels, detemined from 93 bladder tumor tissue samples,
did not correlate with the clinical parameters of progression
considered or with prognosis. More recently, immunohisto-
chemical studies by Carrascosa et al. [161] on 32 patients
with invasive bladder carcinoma further confirmed these ob-
servations. These findings render the clinical role of CD
in bladder cancer controversial. It appears likely the con-
flicting results are due to different methods and numbers of
patients used in these studies. Moreover, as CD in stromal
cells seems to modulate the invasive activity of this cancer
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[156, 158] this phenomenon should be taken into account in
evaluating the prognostic significance of this enzyme. These
observations indicate that among the analytical methods
used to assess the clinical role of CD in bladder cancer im-
munohistochemical methods which can separately assess the
prognostic impact of CD expression in tumor cells or stromal
cells appear to be the more reliable than other methods.
Further investigations with well standardized immunocyto-
chemical methods may better clarify the clinical role of CD
in bladder carcinoma.
Cathepsin D in melanoma and other skin tumors
There is a clear evidence that a number of intracellular
and extracellular proteolytic enzymes may play a major
role in the onset and progression of melanoma and other
skin tumors [162–165]. In fact several in vitro studies have
shown that human melanoma cells may release different pro-
teinases, including CD, which may cooperate to degrade
the extracellular matrix, thus facilitating the invasion of this
tumor [31–33, 162, 166]. Immunohistochemical, immun-
oenzymatic and biochemical studies have shown that CD
is markedly expressed either in vitro in human metastatic
melanoma cells or in vivo in primary and metastatic melan-
oma tissue [166–171]. Interestingly, some of these invest-
igations evidenced, by immunohistochemistry and Western
blot analysis, that CD was always present in dysplastic nevi
but only in 18% of nevocellular nevi while it was absent in
normal melanocytes [166, 167]. These observations were
further indication that the presence of this enzyme seemed
to be associated with melanoma development and progres-
sion and that it might be of clinical interest as a prognostic
marker. This hypothesis has been confirmed by a number
of clinical investigations which have reported a significant
correlation between CD expression levels, determined by
immunocytochemistry, in primary melanoma tissue and poor
clinical outcome [169–171]. On the contrary, other biochem-
ical studies have shown that CD plasma levels were not of
clinical value for identifying patients with malignant melan-
oma at high risk of recurrence. The correlation between
CD expression and aggressive behavior of tumors has been
observed also in other skin tumors. Immunohistochemical
studies by Kawada et al. [173] showed that CD expression
increased in SCC, but not in patients with Bowen’s disease,
seborrhoic keratosis or basal cell carcinoma (BCC). More
recently, Goldmann et al. [174], by analyzing the immun-
ostaining pattern of CD expression in 53 specimens from
primary SCC of the skin, noted that CD and type-IV colla-
genase were significantly overexpressed at the invading front
of metastasized tumors, as compared to those which were
not. These findings suggested that CD, in concert with other
proteolytic enzymes, may be also involved in the SCC skin
invasion. These results suggest that CD may be of value as
biochemical marker to identify highly aggressive forms of
these tumors and therefore to identify high-risk patients for
adjuvant therapy [162, 170, 171].
Cathepsin D as therapeutic target in cancer treatment
The experimental and clinical findings suggesting a role for
CD in tumor progression, imply that the modulation of its
biological activity by the use of its specific inhibitors or an-
tibodies may have a clinical relevance in the treatment of
solid neoplasms. Experimental in vitro and in vivo studies
showed that anti-CD antibodies significantly reduced, in a
dose-dependent fashion, the invasive potential human glio-
blastoma cells, whereas antibodies raised against the 27–44
activation peptide of pro-CD administered to nude mice with
human breast or prostatic tumors inhibited the growth of
these tumors [63, 140, 141]. However, further investigations
to evaluate the potential clinical applications of these anti-
bodies in cancer treatment have not yet been pursued. On
the other hand, most experimental studies have been carried
out to evaluate the therapeutic activity of specific inhibitors
of CD. These investigations have been mainly undertaken
with pepstatin A, a naturally occurring inhibitor of CD and
other aspartyl proteinases [1, 66]. In vitro studies by Castino
et al. [65] evidenced that this inhibitor, at 100 µM concen-
tration, was cytotoxic for some human neuroblastoma cell
lines. These authors hypothesized that the cytotoxic effects
induced by pepstatin A may be the consequence of the in-
hibition of CD activity which, in these tumor cells, seems
to modulate caspase-dependent apoptosis [9, 57, 65]. On
the other hand, our previous in vivo studies showed that the
intraperitoneal administration of pepstatin A induced a sig-
nificant reduction in the number of spontaneous lung or liver
metastases in mice transplanted with Lewis Lung carcinoma,
MCa mammary carcinoma or M5076 ovarian reticulum cell
sarcoma but not in B16 melanoma or L1210-tumor bearing
mice [66, 175]. Interestingly, the administration of pepstatin
A in combination with an antitumor agent with a broad
spectrum of activity such as doxorubicin, to Lewis Lung or
M5076-tumor-bearing mice, resulted in an additive effect on
metastasis formation as compared to that induced by each
single agent [66]. The inhibiting effects of pepstatin A on
metastasis formation did not seem to be due to the direct
cytotoxic activity of this agent on tumor cells, as the growth
of primary tumors in mice was not affected by its administra-
tion. Moreover, our preliminary in vitro experiments showed
that this inhibitor, at concentrations of up to 1× 10−5 M,
(i.e., 10 times lower than that tested by Castino et al. [65]
on human neuroblastoma cells), induced in Lewis Lung or
M5076 tumor cells, a marked inhibition of intracellular CD
activity, but no citotoxic effects. It could, thus, be specu-
lated that the inhibition of CD activity may also account
for the therapeutic activity of pepstatin A. However, other
unknown pharmacological effects induced by this inhibitor
as well as the inhibition of other aspartyl proteinases which
may account for its antimetastatic activity cannot be ruled
out. Nevertheless, these findings suggest a potential role of
pepstatin A and its analogs in the adjuvant therapy of solid
tumors [25, 65, 66, 176]. However, more detailed inform-
ation about the pharmacological and toxicological profile
of these substances, as well as on their range of activity
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is needed before assessing their potential clinical value in
cancer treatment.
Conclusions
Experimental and clinical observation indicate that CD may
facilitate the growth and spread of solid tumors by acting
at various phases of this process (Figure 1). Other evid-
ence suggests that CD may also be involved in upstream
events of tumor progression such as carcinogenesis. This
latter hypothesis is supported by some in vitro studies which
reported that the intracellular expression levels of CD were
significantly altered during the oncogenic transformation of
murine fibroblasts, or during the conversion of nontumori-
genic colon adenoma-derived cells to a highly tumorigenic
phenotype [177, 178]. These results might also, in part, ac-
count for the increased serum levels of this enzyme noted
in certain pre-malignant conditions [121, 123, 124, 128,
129]. Therefore, the evaluation of CD expression levels in
tumor tissues, and/or body fluids, is proposed as prognostic
parameter for predicting the clinical outcome for cancer pa-
tients [179]. Although, there is, to date, a general consensus
on the prognostic role of CD in female breast cancer [19,
26, 37, 38, 179], conflicting results have been obtained in
other gynecological tumors, as well as in other solid neo-
plasms (Table 2). These discrepant results have been, in
part, explained with: i) the different methods used to de-
termine CD expression: it is well known that, biochemical
or immunoenzymatic assay methods, unlike immunohisto-
chemical methods, measure total CD activity or content from
tumor cells, stromal cells and other non-tumor cells. The
presence of CD in stromal cells, which may influence the
aggressive behaviour of tumors, may affect the concentra-
tion of this enzyme in tumor homogenates and consequently
its prognostic significance [80, 91, 93, 103, 109–111, 155,
158, 179, 180]; ii) with the different monoclonal or poly-
clonal antibodies used, as they may detect single or multiple
variations of form of enzyme or may also be unable to detect
other altered forms of the enzyme secreted by tumor cells
[179]; iii) with the subjective methods of scoring to evaluate
the staining intensity of the enzyme; iv) with different cut-
off levels considered [179]; v) with the different number and
selection of patients; vi) with the different follow-up periods
considered. Therefore, further clinical studies, with more
appropriate standardized techniques, may better assess the
prognostic significance of CD in solid tumors. Nevertheless,
these investigations provided evidence that CD expression in
some tumors may significantly correlate to more aggressive
forms of solid neoplasms. These findings are further cor-
roborated by observation which reported that altered levels
of the proteinase in tumor cells may be associated, either
in vitro or in vivo, with the onset of resistance, or degree
of chemosensitivity to antitumor drugs [43, 50, 55, 76].
Moreover, a number of experimental studies reported that,
in some tumors, CD appears to mediate the apoptotic effects
induced by some cytokines, antitumor drugs or differenti-
ating agents [10, 181]. The mechanisms involved in these
processes are still controversial, though recent findings in-
dicate that CD may modulate p53-mediated apoptosis and
cell chemosensitivity to antitumor agents [182]. Clinical
studies which have shown a significant correlation between
CD and P53 overexpression in different tumors, support this
hypothesis [81, 117, 155, 158, 183]. These findings sug-
gest that CD may be also viewed as a potential attractive
target for the drawing-up of new therapeutic strategies in the
treatment of solid tumors, and in circumventing the onset of
antitumor drug-induced resistance.
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